NCT01022853 2018-07-30
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
3 trialsNCT00998296 2015-08-19
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
Boehringer Ingelheim
Phase 1 Completed
NCT00715403 2014-12-02
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Boehringer Ingelheim
Phase 1 Completed